How effective is Osimertinib in patients with advanced lung cancer?

Active substance in Osimertinib Osimertinib is a cancer drug called a tyrosine kinase inhibitor that blocks the activity of EGFR, which normally controls cell growth and division. In lung cancer cells, EGFR is often overactive, causing cancer cells to grow uncontrollably. By blocking EGFR, osimertinib helps reduce the growth and spread of cancer. It's only available by prescription, and before starting treatment, doctors should use genetic testing to confirm whether a patient has the EGFR mutation. Patients take 80 mg once a day until the disease improves or remains stable, or does not relapse after surgery, and the side effects are tolerable. If certain side effects occur, your doctor may decide to reduce the dose or stop treatment.